GlassScriptPhysician profile
James M Chamberlain
NPI 1437150042
$8,045.93
in general payments reported to CMS, 2019-2025
54 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $958 · 2021: $1,368 · 2022: $936 · 2023: $1,202 · 2024: $1,067 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.43 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,205.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $779.81 | 2019-2025 | Otezla, Repatha, Prolia |
| Abbvie INC. | $445.32 | 2021-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $413.59 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $411.62 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $359.22 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $328.19 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $310.84 | 2019-2025 | |
| Abbott Laboratories | $298.38 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $286.09 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.35 | 2019-2024 | Tradjenta, Jardiance |
| Dexcom, INC. | $231.78 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $134.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $133.73 | 2020-2024 | Rexulti |
| Exact Sciences Corporation | $122.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.